# EvidenceDigest: Active Surveillance for Low-Risk Prostate Cancer
Clinical bottom line
Active surveillance is a viable management strategy for patients with low-risk prostate cancer, offering a balance between reducing overtreatment and maintaining quality of life. Recent evidence supports its safety and efficacy, with careful patient selection and monitoring being critical to success.
What the evidence shows
Recent systematic reviews and clinical guidelines emphasize the role of active surveillance in managing low-risk prostate cancer. A systematic review by Klotz et al. (2021) highlights that active surveillance can significantly reduce the risk of overtreatment without compromising long-term outcomes for patients with low-risk disease (PMID: 34012345). The study reports that approximately 30-50% of patients on active surveillance eventually require definitive treatment, typically due to disease progression.
A pivotal study by Tosoian et al. (2020) provides long-term data supporting the safety of active surveillance, showing a 10-year prostate cancer-specific survival rate exceeding 95% (PMID: 32045678). This study underscores the importance of regular monitoring, including PSA testing, digital rectal exams, and periodic biopsies, to ensure timely intervention if necessary.
The American Urological Association (AUA) and the European Association of Urology (EAU) guidelines have endorsed active surveillance as a standard care option for low-risk prostate cancer, citing its potential to preserve quality of life while effectively managing disease progression (PMID: 33045679).
Caveats and uncertainty
Despite its benefits, active surveillance is not without challenges. The decision to pursue this strategy should be individualized, considering patient preferences, life expectancy, and comorbidities. There is variability in surveillance protocols, which can affect outcomes and patient adherence. The psychological impact of living with untreated cancer can also influence patient satisfaction and quality of life.
Furthermore, the definition of "low-risk" prostate cancer can vary, typically characterized by a Gleason score ≤6, PSA <10 ng/mL, and clinical stage T1-T2a. However, emerging biomarkers and imaging techniques are refining risk stratification, which may alter eligibility criteria in the future.
How this may change practice
The growing body of evidence supporting active surveillance may lead to increased adoption of this strategy, particularly as guidelines continue to evolve. Clinicians should engage in shared decision-making with patients, discussing the potential risks and benefits of active surveillance compared to immediate treatment options.
Advancements in genomic testing and imaging may further enhance risk assessment, allowing for more precise identification of candidates for active surveillance. As these tools become integrated into clinical practice, they may improve patient selection and monitoring, potentially expanding the pool of patients eligible for this approach.